메뉴 건너뛰기




Volumn 3, Issue 1, 2005, Pages 71-72

Ostomy care: The added considerations for cancer patients

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; VASCULOTROPIN INHIBITOR;

EID: 15544378688     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (1)

References (3)
  • 1
    • 14644434982 scopus 로고    scopus 로고
    • Cancer Therapy Evaluation Program Available at Accessed November 15
    • Cancer Therapy Evaluation Program: Common Toxicity Criteria, version 2.0. Available at: http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf. Accessed November 15, 2004.
    • (2004) Common Toxicity Criteria, Version 2.0
  • 2
    • 0042744792 scopus 로고    scopus 로고
    • Quality of life of stoma patients: Temporary ileostomy versus colostomy
    • Silva MA, Ratnayake G, Deen KI. Quality of life of stoma patients: temporary ileostomy versus colostomy. World J Surg 2003;27:421-424.
    • (2003) World J. Surg. , vol.27 , pp. 421-424
    • Silva, M.A.1    Ratnayake, G.2    Deen, K.I.3
  • 3
    • 3543073757 scopus 로고    scopus 로고
    • Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer: Updated results from the Eastern Cooperative Oncology Group (ECOG) Study E2200
    • Program and abstracts of the 2004 Gastrointestinal Cancers Symposium; January 22-24, San Francisco, California. Abstract 289
    • Giantonio BJ, Levy D, Catalano P, et al. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer: updated results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. Program and abstracts of the 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, California. Abstract 289.
    • (2004)
    • Giantonio, B.J.1    Levy, D.2    Catalano, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.